In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomized phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. All participants assigned to receive placebo in the IPERGAY trial will be offered intermittent Truvada PrEP.
Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss highlights from this summer's International AIDS Conference, the largest and most comprehensive global meeting on the medical, public health, and social aspects of HIV and AIDS.
Highlights of this overview include the HIV cascade of care, developments in antiretroviral therapy, pre-exposure prophylaxis (PrEP) and other HIV prevention news, and new hepatitis C treatment for people with HIV/HCV coinfection.
HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.
Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.
HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.
Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.